Can we eliminate auto-SCT for patients with MCL?

During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Marco Ladetto, SS Antonio e Biagio e Cesare Arrigo, Alessandria, IT, who discussed the role of autologous stem cell transplant (auto-SCT) for mantle cell lymphoma (MCL) in 2020.

Marco Ladetto starts by introducing what role auto-SCT plays in MCL and indicates that it must be considered in the context of full treatment protocols. He goes on to say, however, that medicine must continue to advance, and one way in which this can be done is through examination of the results of large phase III trials, such as TRIANGLE.

Ladetto discusses the heterogeneous nature of MCL and how different subsets respond to high-dose chemotherapy. The impact of some key mutations are also described.